Our Pipeline
Differentiated pipeline based on transformative innovations
Our rich pipeline has the potential to shift ophthalmic treatment paradigms and make a real difference in patients’ lives
Product Candidate
Investigational indication
Preclinical
Phase 1
Phase 2
Phase 3
OCS-01
OCS-02
OCS-05
Other Candidates
OCS-01
Product Candidate
Investigational indication
Preclinical
Phase 1
Phase 2
Phase 3
Product Candidate
Investigational indication
Preclinical
Phase 1
Phase 2
Phase 3
Product Candidate
Investigational indication
Preclinical
Phase 1
Phase 2
Phase 3
OCS-02
OCS-05
Product Candidate
Investigational indication
Preclinical
Phase 1
Phase 2
Phase 3
Product Candidate
Investigational indication
Preclinical
Phase 1
Phase 2
Phase 3
Other Candidates
Product Candidate
Investigational indication
Preclinical
Phase 1
Phase 2
Phase 3
Product Candidate
Investigational indication
Preclinical
Phase 1
Phase 2
Phase 3
The safety and efficacy for OCS-01, OCS-02 and OCS-05 have not been established for any indication as they are investigational drugs and have not received regulatory approval for commercial use in any country.
Our Potential to Transform Eye Care and Improve Patient Outcomes
Rethinking Ophthalmology to Save Sight and Improve Eye Care
We are rethinking ophthalmology by building and constantly advancing our innovative and differentiated pipeline which has the potential to transform eye care and improve vision for patients around the world.”